A Study of LY2922083 in Healthy Participants and Participants With Diabetes

Eli Lilly and Company36 enrolled

Overview

The aim of this trial is to evaluate the safety of the study drug in healthy participants and participants with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study consists of two parts. Part A will study healthy participants in up to 3 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 6 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

PlaceboDRUG

Administered orally as capsules

LY2922083DRUG

Administered orally as capsules

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: For all participants : * Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes * Have a screening body mass index (BMI) of at least 18.0 kilograms per square meter (kg/m\^2) * Have blood pressure, pulse rate, blood and urine laboratory test results acceptable for the study For participants with T2DM: * Do not have any change to their diabetes treatment (exercise with or without metformin) for at least 4 weeks prior to screening * Have a glycated hemoglobin (HbA1c) value of greater than or equal to 6% and less than or equal to 11% at screening Exclusion Criteria: For all participants : * Are currently participating in another clinical study or completed one in the last 30 days * Are allergic to LY2922083 or other related drugs * Have a history of significant heart, lung, liver, kidney, stomach or brain disease, or have any medical problems which may cause an increased risk during the study * Have electrocardiogram (ECG) readings that are not suitable for the study * Have a history of hepatitis or jaundice * Are infected with hepatitis B * Are infected with hepatitis C * Are infected with human immunodeficiency virus (HIV) * Have donated more than 450 milliliters (mL) of blood in the last 3 months or have donated any blood in the last month * Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female), or are unwilling to stop alcohol as required by the study restrictions (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits) * Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while at the clinic For participants with T2DM : * Have had heart disease or stroke within 6 months before entering the study * Have health complications due to poorly controlled diabetes as shown by blood and urine laboratory test results or based on physical examination and medical assessment as determined by the study doctor * Have been hospitalized for poor control of diabetes (keto-acidotic episode) in the last 6 months * Have used insulin to control diabetes in the last 1 year * Show symptoms of high blood sugar (for example, frequent urination, always feeling thirsty, or unexpected weight loss)

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Singapore, Singapore

Outcomes

Primary Outcomes

Number of Participants With 1 or More Serious Adverse Event(s) (SAEs)

Events deemed by the Investigator to be SAEs related to study drug administration are reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame: Baseline through study completion (up to 70 days)

Secondary Outcomes

Pharmacokinetics (PK): Area Under the Concentration Curve From Time 0 to Infinite Time [AUC(0-∞)] of LY2922083

Time frame: Predose up to 72 hours (h) after each dose of study drug (Part A: predose, 0.5, 1.5, 2.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose. Part B: predose, 0.5, 1.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose.)

PK: Maximum Concentration (Cmax) of LY2922083

Time frame: Predose up to 72 h after each dose of study drug (Part A: predose, 0.5, 1.5, 2.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose. Part B: predose, 0.5, 1.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose.)

Change From Baseline in Blood Glucose Area Under the Effective Concentration Curve From Time 0 to 24 h Postdose [AUEC(0-24)]

Least Squares (LS) mean values were adjusted for baseline, treatment, period, treatment sequence, participant and error.

Time frame: Baseline (predose for Part A and Day -1 time-matched for Part B), up to 24 h postdose (1.5, 2.5, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, and 24 h postdose)

Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time 0 to 6 h Postdose [AUEC(0-6)]

LS mean values were adjusted for baseline, treatment, period, treatment sequence, participant and error.

Time frame: Baseline (predose for Part A and Day -1 time-matched for Part B), up to 6 h postdose (1.5, 2.5, 4, 4.5, 5, and 6 h postdose)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.